-
肺癌是世界范围内发病率和死亡率最高的肿瘤,是一个重要的全球健康性问题。非小细胞肺癌作为肺癌最主要的类型,占初诊病人的80%以上[1],5年生存率仅17%左右[2]。肺腺癌作为非小细胞肺癌诊断最多的组织学亚型[3-4],其生存期仍不太理想。虽然肺腺癌有很多新的、疗效较好的治疗方法,如靶向治疗、免疫治疗等,但全身化疗仍为重要的治疗方法。现如今尽管化疗的疗效有所提高,但晚期肺癌病人的预后仍较差。因此,早期识别和确定预后指标对提高病人生活质量和延长生存期颇为重要。越来越多的证据[5-6]表明,中性粒细胞淋巴细胞比值(NLR)和血小板淋巴细胞比值(PLR)是系统性炎症和免疫反应的潜在指标,且这些比值易于计算,已被明确为胃癌[7]、胆管癌[8]、肝癌[9]、非小细胞肺癌[10]、乳腺癌[11]、结肠癌[12]预后的预测标志物。目前监测NLR及PLR动态变化与一线化疗疗效关系的研究较少,现就NLR及PLR动态变化与晚期肺腺癌病人一线化疗疗效及预后关系作一探究。
-
NLR0、NLR2、PLR0、PLR2在2周期化疗后PD组的水平明显高于CR+PR+SD组(P<0.01)。NLR0、NLR2、NLR4、PLR0、NLR2、NLR4在4周期化疗后PD组的水平高于CR+PR+SD组(P<0.01)(见表 1)。
变量 2周期化疗后疗效 Z P 4周期化疗后疗效 Z P CR+PR+SD PD CR+PR+SD PD NLR0 2.69(1.95, 3.56) 4.27(2.07, 6.40) -3.16 < 0.01 2.70(1.89, 3.56) 3.70(2.40, 5.58) -3.14 < 0.01 NLR2 1.86(1.47, 2.49) 2.90(1.69, 5.75) -3.56 < 0.01 1.86(1.47, 2.52) 2.49(1.66, 4.94) -3.30 < 0.01 NLR4 1.79(1.26, 2.55) 3.50(2.67, 6.30) -6.10 < 0.01 PLR0 134.30(107.96, 179.89) 205.85(125.90, 322.95) -3.93 < 0.01 142.43(105.61, 185.08) 190.20(129.17, 277.88) -3.79 < 0.01 PLR2 151.92(122.35, 206.40) 243.87(152.59, 362.42) -3.96 < 0.01 153.02(123.45, 213.65) 184.62 (143.52, 331.43) -2.55 < 0.01 PLR4 137.64(100.00, 175.69) 215.09(136.20, 290.72) -4.21 < 0.01 表 1 NLR、PLR与2、4周期化疗后疗效关系[M(P25, P75)]
-
Spearman相关分析表明193例肺癌病人总生存期与NLR0、NLR4、PLR0、PLR2、PLR4、2周期疗效、4周期疗效呈负相关关系(P < 0.05~P < 0.01)(见表 2)。
变量 NLR0 NLR4 PLR0 PLR2 PLR4 生存期 -0.249** -0.199** -0.143* -0.212** -0.143* 2周期后疗效 -0.228** -0.069 -0.284** -0.286** -0.202** 4周期后疗效 -0.227** -0.440** -0.273** -0.184** -0.304** *P < 0.05,**P < 0.01 表 2 NLR、PLR与生存期及疗效间的相关分析(r)
-
对NLR0、NLR4、PLR0、PLR2、PLR4、N分期、2周期疗效、4周期疗效进行单因素分析,发现除N分期外(P>0.05),NLR0、NLR4、PLR0、PLR2、PLR4对OS的影响均有统计学意义(P < 0.01)(见表 3),生存曲线见图 1~8。
分组 n 中位/平均生存期/d 95%CI Z P 下限 上限 N分期 N0 39 859 455.64 1 262.36 2.03 >0.05 N1+2+3 154 745 540.04 949.06 NLR0 ≥3.39 124 510 400.5 619.5 17.75 < 0.01 < 3.39 69 876 730.8 1 021.2 NLR4 ≥2.54 74 515 494.5 535.5 17.39 < 0.01 < 2.54 119 878 682.2 1 073.8 PLR0 ≥186.48 57 504 388.00 620.00 28.34 < 0.01 < 186.48 136 928 717.56 1 138.44 PLR2 ≥170.50 88 513 449.35 576.65 35.11 < 0.01 < 170.50 105 1 357 963.06 1 750.94 PLR4 ≥137.64 1076 558 485.49 631.62 93.92 < 0.01 < 137.64 86 1 673 1 469.72 1 896.94 2周期化疗后疗效 CR+PR+SD 155 792 274.44 687.56 8.93 < 0.01 PD 38 481 274.44 687.56 4周期化疗后疗效 CR+PR+SD 148 859 731.47 986.53 18.39 < 0.01 PD 15 504 349.82 658.18 表 3 影响193例肺癌病人Kaplan-Meier生存分析
-
在校正病人NLR0、NLR2、NLR4、PLR0、PLR2、PLR4、2周期化疗后疗效及4周期化疗后疗效等因素后,多因素分析表明,NLR0与PLR4是生存期的独立预测因素(P < 0.05和P < 0.01),而NLR4、PLR0、PLR2及2、4周期化疗疗效与生存期的关系无统计学意义(P>0.05)(见表 4)。
变量 B SE Waldχ2 P Exp(β) 95%CI NLR0 -0.529 0.25 4.32 < 0.05 0.589 0.358~0.970 NLR4 0.066 0.25 0.07 >0.05 1.068 0.651~1.752 PLR0 0.099 0.24 0.17 >0.05 1.104 0.687~1.774 PLR2 0.365 0.24 2.31 >0.05 0.695 0.434~1.111 PLR4 -3.738 0.73 26.49 < 0.01 0.024 0.006~0.099 2周期化疗疗效 0.048 0.27 0.03 >0.05 1.049 0.624~1.764 4周期化疗疗效 0.418 0.26 2.60 >0.05 1.520 0.914~2.527 表 4 影响193例肺腺癌病人预后的多因素分析
动态监测NLR、PLR变化与晚期肺腺癌一线化疗疗效及预后关系
Relationship between dynamic monitoring NLR and PLR, and efficacy of first-line chemotherapy and prognosis of advanced lung adenocarcinoma
-
摘要:
目的探讨中性粒细胞淋巴细胞比率(NLR)及血小板淋巴细胞比率(PLR)的动态变化对晚期肺腺癌病人化疗疗效及生存期的预测价值。 方法回顾性分析193例经一线化疗的晚期肺腺癌病人病历资料,收集其化疗前、化疗2周期后及化疗4周期后的相关资料进行疗效评定,并分别计算NLR、PLR;分析NLR、PLR的动态变化与各种临床特征、一线化疗疗效及总生存期(OS)之间的关系。 结果NLR、PLR水平在化疗前及化疗后疾病进展组均高于完全缓解+部分缓解+疾病稳定组(P < 0.01);在化疗疗效方面,除NLR4(P>0.05)外,NLR0、NLR2、PLR0、PLR2、PLR4与2周期化疗疗效呈负相关关系(P < 0.05~P < 0.01);而NLR0、NLR2、NLR4、PLR0、PLR2、PLR4与4周期化疗疗效均呈负相关关系(P < 0.01);Kaplan-Meier生存分析表明,OS在不同NLR0、NLR4、PLR0、PLR2、PLR4、2周期化疗疗效及4周期化疗疗效中差异均有统计学意义(P < 0.01),且多因素分析表明,NLR0与PLR4是生存期的独立危险因素(P < 0.05和P < 0.01)。 结论NLR、PLR与一线化疗晚期肺腺癌疗效及生存密切相关,治疗前NLR与化疗4周后PLR是一线化疗晚期肺腺癌病人的独立预后因素。 -
关键词:
- 肺腺癌 /
- 总生存期 /
- 中性粒细胞淋巴细胞比率 /
- 血小板淋巴细胞比率
Abstract:ObjectiveTo investigate the predictive value of dynamic monitoring the neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) in the chemotherapeutic effects and lifetime of lung adenocarcinoma patients. MethodsThe clinical data of 193 advanced lung adenocarcinoma patients treated with first-line chemotherapy were retrospectively analyzed.The relevant data of patients before chemotherapy, after 2 and 4 cycles of chemotherapy were collected.The curative effects of patients were evaluated, and the NLR and PLR were calculated.The relationship between the dynamic changes of NLR and PLR, and various clinical features, first-line chemotherapy efficacy and overall survival(OS) were analyzed. ResultsThe levels of NLR and PLR in PD group before and after chemotherapy were higher than those in CR group, PR group and SD group(P < 0.01).In terms of the efficacy of chemotherapy, except for NLR4(P>0.05), the NLR0, NLR0, PLR0, PLR2 and PLR4 were negatively correlated with the efficacy of 2-cycle chemotherapy(P < 0.05 to P < 0.01).The NLR0, NLR2, NLR4, PLR0, PLR2 and PLR4 were negatively correlated with the efficacy of 4-cycle chemotherapy(P < 0.01).The results of Kaplan-Meier survival analysis showed that the OS was significantly correlated with the NLR0, NLR4, PLR0, PLR2, PLR4, efficacy of 2-cycle chemotherapy and efficacy of 4-cycle chemotherapy(P < 0.01).The results of multivariate analysis showed that the NLR0 and PLR4 were the independent risk factors of survival(P < 0.05 and P < 0.01). ConclusionsThe NLR and PLR are closely related to the efficacy and survival of first-line chemotherapy for advanced lung adenocarcinoma.The NLR before treatment and PLR after 4 cycle chemotherapy are the independent prognostic factors of advanced lung adenocarcinoma patients treated with first-line chemotherapy. -
表 1 NLR、PLR与2、4周期化疗后疗效关系[M(P25, P75)]
变量 2周期化疗后疗效 Z P 4周期化疗后疗效 Z P CR+PR+SD PD CR+PR+SD PD NLR0 2.69(1.95, 3.56) 4.27(2.07, 6.40) -3.16 < 0.01 2.70(1.89, 3.56) 3.70(2.40, 5.58) -3.14 < 0.01 NLR2 1.86(1.47, 2.49) 2.90(1.69, 5.75) -3.56 < 0.01 1.86(1.47, 2.52) 2.49(1.66, 4.94) -3.30 < 0.01 NLR4 1.79(1.26, 2.55) 3.50(2.67, 6.30) -6.10 < 0.01 PLR0 134.30(107.96, 179.89) 205.85(125.90, 322.95) -3.93 < 0.01 142.43(105.61, 185.08) 190.20(129.17, 277.88) -3.79 < 0.01 PLR2 151.92(122.35, 206.40) 243.87(152.59, 362.42) -3.96 < 0.01 153.02(123.45, 213.65) 184.62 (143.52, 331.43) -2.55 < 0.01 PLR4 137.64(100.00, 175.69) 215.09(136.20, 290.72) -4.21 < 0.01 表 2 NLR、PLR与生存期及疗效间的相关分析(r)
变量 NLR0 NLR4 PLR0 PLR2 PLR4 生存期 -0.249** -0.199** -0.143* -0.212** -0.143* 2周期后疗效 -0.228** -0.069 -0.284** -0.286** -0.202** 4周期后疗效 -0.227** -0.440** -0.273** -0.184** -0.304** *P < 0.05,**P < 0.01 表 3 影响193例肺癌病人Kaplan-Meier生存分析
分组 n 中位/平均生存期/d 95%CI Z P 下限 上限 N分期 N0 39 859 455.64 1 262.36 2.03 >0.05 N1+2+3 154 745 540.04 949.06 NLR0 ≥3.39 124 510 400.5 619.5 17.75 < 0.01 < 3.39 69 876 730.8 1 021.2 NLR4 ≥2.54 74 515 494.5 535.5 17.39 < 0.01 < 2.54 119 878 682.2 1 073.8 PLR0 ≥186.48 57 504 388.00 620.00 28.34 < 0.01 < 186.48 136 928 717.56 1 138.44 PLR2 ≥170.50 88 513 449.35 576.65 35.11 < 0.01 < 170.50 105 1 357 963.06 1 750.94 PLR4 ≥137.64 1076 558 485.49 631.62 93.92 < 0.01 < 137.64 86 1 673 1 469.72 1 896.94 2周期化疗后疗效 CR+PR+SD 155 792 274.44 687.56 8.93 < 0.01 PD 38 481 274.44 687.56 4周期化疗后疗效 CR+PR+SD 148 859 731.47 986.53 18.39 < 0.01 PD 15 504 349.82 658.18 表 4 影响193例肺腺癌病人预后的多因素分析
变量 B SE Waldχ2 P Exp(β) 95%CI NLR0 -0.529 0.25 4.32 < 0.05 0.589 0.358~0.970 NLR4 0.066 0.25 0.07 >0.05 1.068 0.651~1.752 PLR0 0.099 0.24 0.17 >0.05 1.104 0.687~1.774 PLR2 0.365 0.24 2.31 >0.05 0.695 0.434~1.111 PLR4 -3.738 0.73 26.49 < 0.01 0.024 0.006~0.099 2周期化疗疗效 0.048 0.27 0.03 >0.05 1.049 0.624~1.764 4周期化疗疗效 0.418 0.26 2.60 >0.05 1.520 0.914~2.527 -
[1] FOSSELLA F.Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the tax 326 study group[J].J Clin Oncol, 2003, 21(16):3016. doi: 10.1200/JCO.2003.12.046 [2] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2015[J].CACA J Clin, 2015, 65(1):5. doi: 10.3322/caac.21254 [3] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2016[J].CACA J Clin, 2016, 66(1):7. doi: 10.3322/caac.21332 [4] MILLER KD, SIEGEL RL, LIN CC, et al.Cancer treatment and survivorship statistics, 2016[J].CA J Clin, 2016, 66(4):271. doi: 10.3322/caac.21349 [5] SARA SF, FERNANDES JR PAULO CéSAR, BARBOSA SILVA MARCELO JOSé, et al.The neutrophil-to-lymphocyte ratio:a narrative review[J].Ecancermedicalscience, 2016, 10:702. [6] MARCHIONI M, PRIMICERI G, INGROSSO M, et al.The clinical use of the neutrophil to lymphocyte ratio (nlr) in urothelial cancer:a systematic review[J].Clin Genitourin Cancer, 2016, 14(6):473. doi: 10.1016/j.clgc.2016.04.008 [7] MIYAMOTO R, INAGAWA S, SANO N, et al.Theneutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J].Eur J Surg Oncol, 2018, 44(5):607. doi: 10.1016/j.ejso.2018.02.003 [8] KITANO Y, YAMASHITA YI, YAKAMURA K, et al.Effects of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinoma[J].Anticancer Res, 2017, 37(6):3229. [9] YANG HJ, JIANG JH, LIU QA, et al.Preoperative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection[J].Tumour Biol, 2017, 39(6):1010428317707375. [10] YUAN C, LI N, MAO X, et al.Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer:Results from a large cohort[J].Thorac Cancer, 2017, 8(4):350. doi: 10.1111/1759-7714.12454 [11] IIMORI N, KASHIWAGI S, ASANO Y, et al.Clinical significance of the neutrophil-to-lymphocyte ratio in endocrine therapy for stage Ⅳ breast cancer[J].In Vivo, 2018, 32(3):669. [12] ZHANG J, ZHANG HY, LI J, et al.The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer:a systematic review and meta-analysis[J].Oncotarget, 2017, 8(40):68837. doi: 10.18632/oncotarget.18575 [13] NISHINO M, JACKMAN DM, HATABU H, et al.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non small cell lung cancer:comparison with original RECIST and impact on assessment of tumor response to targeted therapy[J].AJR Am J Roentgenol, 2010, 195(3):W221. doi: 10.2214/AJR.09.3928 [14] 张文, 张鹏, 徐雪莹, 等.中性粒细胞在肿瘤中作用的研究进展[J].肿瘤, 2017, 37(1):96. doi: 10.3969/j.issn.1672-4992.2017.01.026 [15] COFFELT SB, WELLENSTEIN MD, DE VISSER KE.Neutrophils in cancer:neutral nomore[J].Nat Rev Cancer, 2016, 16(7):431. doi: 10.1038/nrc.2016.52 [16] YAN W, XU H, WENYING X.Prognostic value of a novel scoring system using inflflammatory response biomarkers in non-small cell lung cancer:a retrospective study[J].Thorac Cancer, 2019, 10(6):1402. doi: 10.1111/1759-7714.13085 [17] VAN EGMOND M.BAKEMA JE.Neutrophils as effector cells for antibody-based immunotherapy of cancer[J].Semin Cancer Biol, 2013, 23(3):190. doi: 10.1016/j.semcancer.2012.12.002 [18] JIN H, ZHANG G, LIU X, et al.Blood neutrophil-lymphocyte ratio predicts survival for stages Ⅲ-Ⅳ gastric cancer treated with neoadjuvant chemotherapy[J].World J Surg Oncol, 2013, 11(1):12. doi: 10.1186/1477-7819-11-12 [19] BANAT GA, TRETYN A, PULLAMSETTI SS, et al.Immune and inflammatory cell composition of human lung cancer stroma[J].PLos One, 2015, 10(9):e0139073. doi: 10.1371/journal.pone.0139073 [20] DERMAN BA, MACKLIS JN, AZEEM MS, et al.Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer[J].BMC Cancer, 2017, 17(1):141. doi: 10.1186/s12885-017-3122-y [21] WANG J, KALHOR N, HU J, et al.Pretreatment neutrophil to lymphocyte ratio is associated with poor survival in patients with stage i-iii non-small cell lung cancer[J].PLoS One, 2016, 11(10):e0163397. doi: 10.1371/journal.pone.0163397 [22] BAMBACE NM, HOLMES CE.The platelet contribution to cancer progression[J].J Thromb Haemost, 2011, 9(2):237. doi: 10.1111/j.1538-7836.2010.04131.x [23] MORIMOTO K, SATOH-YAMAGUCHI K, HAMAGUCHI A, et al.Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs[J].Oncogene, 2008, 27(3):264. doi: 10.1038/sj.onc.1210645 [24] DIEM S, SCHMID S, KRAPF M, et al.Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab[J].Lung Cancer, 2017, 111:176. doi: 10.1016/j.lungcan.2017.07.024 [25] SONG XY, CHEN DW, MA Y, et al.Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy[J].Cancer Manag Res, 2018, 10:6677. doi: 10.2147/CMAR.S188578 [26] QIANG G, LIANG C, XIAO F, et al.Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer:a meta-analysis[J].Onco Targets Ther, 2016, 9:869. [27] KANG KH, EFIRD JT, SHARMA N, et al.Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage Ⅲ non-small-cell lung cancer[J].Future Oncol, 2017, 13(16):1405. doi: 10.2217/fon-2017-0045 [28] PINATO DJ, SHINER RJ, SECKL MJ, et al.Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer[J].Br J Cancer, 2014, 110(8):1930. doi: 10.1038/bjc.2014.145 [29] LIU HB, WU Y, WANG ZF, et al.Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer[J].J Thorac Dis, 2013, 5(6):783. [30] YAO Y, YUAN D, LIU H, et al.Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy[J].Cancer Immunol Immunother, 2013, 62(3):471. doi: 10.1007/s00262-012-1347-9 [31] 易福梅, 顾阳春, 陈森, 等.治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J].中国肺癌杂志, 2018, 21(6):481.